These cellular changes translate to a strongly diminished occurrence of skeletal metastases in vivo, and in turn may explain the correlation of TRAIL-R2 expression with unfavorable prognostic parameters in clinical breast cancer samples [13]. The gene discussed is TNFRSF10B; the disease is breast carcinoma.